### EVT801: Investigating anti-tumour approach

**Targeting tumour angiogenesis with the selective VEGFR-3 inhibitor EVT801 in cancer immunotherapy**

**EVT801 activity on tumour microenvironment**

**Inclusion criteria**
- Subjects of any gender aged 18 years or older at the time of the study entry.
- Histologically confirmed solid or liquid malignancy.
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
- Measurable disease meeting the response evaluation criteria as documented by the investigator.
- Adequate organ and bone marrow function.
- Ability and willingness to provide archived tumour samples, or to undergo pre-treatment tumour biopsy if feasible.
- Life expectancy of greater than 3 months, in the opinion of the investigator.
- ECOG performance status ≤ 2.
- Adequate renal function, defined as serum creatinine ≤ 1.5 mg/dL.
- Adequate hepatic function, defined as AST, ALT ≤ 1.5 X ULN.
- Hematological parameters: absolute neutrophil count (ANC) ≥ 1,500 cells/µL, hemoglobin (Hb) ≥ 9.0 g/dL.
- Platelet count ≥ 100,000 cells/µL.
- Serum bilirubin ≤ 1.5 X ULN.
- Adequate platelet count ≥ 100,000 cells/µL.
- Women of childbearing potential must have a negative pregnancy test within 7 days before the first dose of study drug.

**Exclusion criteria**
- Subjects with known or suspected allergy or hypersensitivity to EVT801 or components of the formulation.
- History of another primary malignancy, unless treated with curative intent and with no known active disease for ≥ 2 years prior to study entry.
- Any unresolved toxicity from previous treatment of Grade ≥ 3 at the study entry.
- History of another primary malignancy, except basal cell carcinoma of the skin or cervical dysplasia with no known active disease.
- Subjects with a history of adrenal insufficiency.
- Subjects with a history of any condition that the investigator believes may interfere with the interpretation of the study results.
- Subjects who are pregnant or nursing.
- Subjects who have received or are receiving immunomodulatory therapy within 28 days prior to study entry.

**Overview of patients follow-up**

<table>
<thead>
<tr>
<th>Primary endpoint</th>
<th>Secondary endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>Investigating the impact of EVT801 on tumour microenvironment</td>
<td>Investigating the impact of EVT801 on tumour microenvironment</td>
</tr>
<tr>
<td>Investigating the impact of EVT801 on tumour microenvironment</td>
<td>Investigating the impact of EVT801 on tumour microenvironment</td>
</tr>
</tbody>
</table>

**Safety monitoring**
- Blood pressure measurement to control for blood pressure response to EVT801.
- Monitoring for any adverse events or laboratory abnormalities.

**Conclusion and next steps**
- By the end of February 2024, 26 patients have been treated in six different cohorts for EVT801 doses ranging from 50mg QD to 500mg BID.
- To date, collection of safety data on enrolled patients in stage 1 showed no safety alert.
- Allowing dose escalation until cohort 6.
- Resting samples will include:
  - Fresh whole blood samples
  - Fresh PBMCs
  - FFPE biopsies

**Staining on patients with High Grade Serous Ovarian Cancer (HGSO-OC)**

**Patients with high VEGFR-3 expression**
- Patients with high VEGFR-3 expression who could benefit from combination of EVT801 treatment with immune checkpoint inhibitors.

**VEGFR3 & response & response to immune checkpoint therapies**
- VEGFR3 expression
- PD-1 response
- Time to progression
- Overall survival
- Biomarkers

---

Carlos Gomez-Roca, Philippe Cassier, Michael Fitzgerald, Lisa Davenne, Cristina Costantin, Philippe Rochaix, Jean-Pierre Delord, Andrea Nizzardo, Alessia Tagliavini, Marco Pergher, Pierre Fossé & Marie Mandrau